Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
about
A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancyArtemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataDirect transfer of HRPII-magnetic bead complexes to malaria rapid diagnostic tests significantly improves test sensitivityThe influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic reviewEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineMeasuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring DeviceUpdate on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrineMalaria: an update on current chemotherapy.Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesLopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant womenTime-to-infection by Plasmodium falciparum is largely determined by random factors.Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria.Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsPopulation pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatmentPharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malariaOptimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malariaPopulation pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in UgandaConcomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometricsTreatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphismsArtemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.Safety, pharmacokinetics and efficacy of artemisinins in pregnancy.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.
P2860
Q17485688-62304AB1-C9F3-403D-8B8B-4466580115FFQ26783646-1652CE72-7B68-4DC0-998C-471FE8C52F7AQ27304525-3DB96B57-DEE3-4EC9-9180-8706EAD4663DQ28079877-E2B3B054-5222-481E-A49B-C4401F44EE05Q28542034-75E7B43B-78A6-4251-9BBD-C13F2B85CEDFQ28546804-FAC925C8-4FC0-49BF-9507-87D4DCAE0638Q33635019-F3E93022-E4F5-438D-8ECB-2B17668F67E8Q34034413-F7CCA8EC-8DF9-41EC-AE68-C45D5AEB7CFAQ34058351-71F59FCF-3C33-48B0-B790-2A8E7697696EQ34221884-B98A712D-5465-43E7-B84D-15F3C9025424Q34433106-E8DB2DDF-2D4A-4728-A8C8-7104546F3EEDQ34485984-F36B95E0-59BB-4F37-A237-4FFD81ADB288Q34677891-EA346910-47F3-40E8-B5F5-54BAC1E90004Q34953705-43C9EBA6-F4CA-43F1-BF2F-2AC4AC021617Q34974794-5A17C447-1A98-4198-9184-3C15FE5E6F85Q35030175-4E12D716-850F-4168-BCAC-66369D880CE3Q35191473-50E63D2D-2FB5-486C-879C-A1957B66FA08Q35286119-528E95C9-B952-4FAA-9AB9-B8D11E1057C5Q35363704-25A569F5-4479-42F6-9891-C333D205F65BQ35583982-01A54497-11CE-4BE7-9AE6-EA1C072FBC25Q35598379-04214801-76B9-4FE3-B6CD-484A53602F4FQ35867343-72CC4A02-2A54-4516-9A55-19D0B01D0846Q36017416-F197C284-CACD-4BA2-8420-3560F07368C0Q36075976-6370DD4A-F4B1-48F2-88F4-919EF3DE2506Q36080121-46B631D8-824E-46E4-A075-660285120DFDQ36088256-F2BB030C-6F78-42A9-B3F1-E3A4E4C62D72Q36364248-D5B7B9CD-1DB7-4790-B55C-2241C6FC912AQ36411652-69FB190D-CBB3-435A-B8DC-62D752FEA604Q36438820-2414CBCB-19BF-4A87-96A5-AA2E618B998AQ36468109-78312D7E-C250-4EE4-B4EC-56B12FBA6968Q36508726-F86A812D-F35B-4A82-8EB4-7E9B6E7EDE71Q36552289-E46756D3-25D6-4736-937B-558E6BF14764Q36584636-3492636B-9685-461E-8487-30397740468CQ36644765-39F5C7BB-CCE4-49A8-ACFF-793185237143Q36898678-2AE573E7-D288-4066-9F16-5F7C6835C333Q37038270-588F82CA-7BDA-489D-8048-160485359433Q37263818-9BCC02E0-A361-40F4-B5C3-5E1CA9418278Q37366055-DD43B8A1-BF88-4C00-B53D-A6371B9800EBQ37481908-BFB85C52-D792-4398-A23C-29F70A11880FQ37575742-8430A8C2-AC96-4D1C-912A-49B4DC4549A5
P2860
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@en
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@nl
type
label
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@en
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@nl
prefLabel
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@en
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@nl
P2093
P2860
P50
P921
P356
P1476
Population pharmacokinetics of ...... Plasmodium falciparum malaria.
@en
P2093
Anna Annerberg
Benjamas Kamanikom
Elizabeth A Ashley
Niklas Lindegardh
P2860
P304
P356
10.1128/AAC.00195-09
P407
P50
P577
2009-06-29T00:00:00Z